Discovery of serum protein biomarkers for prostate cancer progression by proteomic analysis

…, MG Taylor, CN Adra, CL Aukim-Hastie… - Cancer genomics & …, 2010 - cgp.iiarjournals.org
Background: The incidence of prostate cancer (PCa) has increased in recent years due to
the aging of the population and increased testing; however, mortality rates have remained …

Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

…, S Larkin, PA Townsend, C Aukim-Hastie… - Nature …, 2018 - nature.com
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified
more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data …

New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era

B Bickers, C Aukim-Hastie - Anticancer research, 2009 - ar.iiarjournals.org
The widespread use of the PSA test has led to increased detection of the disease at earlier
stages and a reduction in the number of patients where metastatic disease is found at …

Proteomics in prostate cancer biomarker discovery

…, B Bickers, J Al-Ruwaili, C Aukim-Hastie… - Expert Review of …, 2010 - Taylor & Francis
Despite advances in molecular medicine, genomics, proteomics and translational research,
prostate cancer remains the second most common cause of cancer-related mortality for men …

Study of cellular oncometabolism via multidimensional protein identification technology

C Aukim-Hastie, SD Garbis - Methods in Enzymology, 2014 - Elsevier
Cellular proteomics is becoming a widespread clinical application, matching the definition
of bench-to-bedside translation. Among various fields of investigation, this approach can be …

[HTML][HTML] Dual-targeting CAR T-cell therapy for refractory multiple myeloma

E Smith, C Aukim-Hastie, M Llobet-Canela - multiplemyelomahub.com
While most chimeric antigen receptor (CAR) T-cell clinical trials are using CAR T-cell products
that target one specific antigen on multiple myeloma (MM) cells, other investigators are …

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation

AJ Camm, G Accetta, G Ambrosio, D Atar, JP Bassand… - Heart, 2017 - heart.bmj.com
Objective We studied evolving antithrombotic therapy patterns in patients with newly diagnosed
non-valvular atrial fibrillation (AF) and ≥1 additional stroke risk factor between 2010 and …

[BOOK][B] Cell-wide metabolic alterations associated with malignancy

L Galluzzi, G Kroemer - 2014 - books.google.com
This new volume of Methods in Enzymology continues the legacy of this premier serial with
quality chapters authored by leaders in the field. This volume covers research methods …

Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF

JP Bassand, G Accetta, AJ Camm, F Cools… - European heart …, 2016 - academic.oup.com
… Editorial support was provided by Claire Aukim-Hastie, Emily Chu, Rae Hobbs, and Jane
Tricker (TRI). SAS programming support was provided by Jagan Allu (TRI). … L

[PDF][PDF] ANNA MARIE PYLE

SP COLOWICK, NO KAPLAN - 2014 - ndl.ethernet.edu.et
Second, the metabolic changes linked to malignant transformation should not be
considered as a general property shared by all types of cancer. It has indeed been clearly …